The Practical Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a High Tuberculosis Burden Setting: a Prospective Multicenter Diagnostic Accuracy Study

Guirong Wang, Mingxiang Huang, Hui Jing, Junnan Jia, Lingling Dong, Fen Wang, Yi Xue, Yunfeng Deng, Guanglu Jiang, Hairong Huang

Abstract

Due to the probability of decreased specificity, the practical value of performing the Xpert MTB/RIF Ultra (Xpert Ultra) assay over the Xpert assay for diagnosing pulmonary tuberculosis (TB) and rifampicin (RIF) resistance in a high TB burden setting was evaluated. Participants were recruited consecutively in three tertiary hospitals in China and allocated to the TB case detection and/or rifampicin (RIF) resistance detection group. Each sputum specimen was subjected to smear, MGIT960 liquid culture, and Xpert, and Xpert Ultra assay in parallel. Drug susceptibility testing was conducted for all recovered isolates in the RIF resistance detection group. In total, 1,079 patients were recruited to the case detection group and 450 to the RIF resistance detection group. Xpert Ultra had higher sensitivity than Xpert (92.26%, 322/349 versus 89.40%, 312/349; \( P = 0.006 \)), whereas the most prominent increase was identified in the smear-negative patients (83.70% versus 78.52%; \( P = 0.039 \)). The specificity of Xpert Ultra was slightly lower than that of Xpert (96.30%, 495/514 versus 98.25%, 505/514; \( P = 0.055 \)). Reclassifying trace results as negative resulted in a 4.01% loss of sensitivity (from 92.26% to 88.25%) accompanied by a 1.37% gain in specificity (from 96.30% to 97.67%). Both the sensitivity (97.64% versus 99.21%, \( P = 0.031 \)) and specificity (96.90% versus 97.21%, \( P = 0.816 \)) of Xpert Ultra and Xpert for detection RIF resistance were comparable. In conclusion, Xpert Ultra could improve the diagnosis of smear-negative pulmonary TB in contrast to the Xpert assay. A high percentage of TB history did not significantly decrease the specificity of the test, which supports the potential role of Xpert Ultra as an initial diagnostic tool for TB.

Importance

Xpert Ultra is more sensitive than Xpert, especially in smear-negative TB. A high percentage of TB history in the non-TB population did not significantly affect the reliability of the assay, which supports the potential role of Xpert Ultra as an initial diagnostic tool for TB.

Keywords

tuberculosis, pulmonary, Xpert Ultra, trace, specificity

Tuberculosis (TB) is a leading cause of infectious disease-related deaths. Globally, an estimated 9.9 million people fell ill with TB in 2020 (1). Of the 4.8 million people diagnosed with pulmonary TB worldwide in 2020, 59% were bacteriologically confirmed (1). In addition, 71% (2.1/3.0 million) of bacteriologically confirmed pulmonary TB patients were tested for rifampicin (RIF) resistance (1). The considerable detection gap was mainly caused by shortage and incapability of diagnostics, especially in high TB burden countries. Therefore, highly sensitive, rapid, and accessible diagnostics are persistently needed.
The WHO recommended the Xpert MTB/RIF assay (Xpert) (Cepheid Inc., Sunnyvale, CA, USA) as the initial test for pulmonary TB in 2010 (2). Xpert shows excellent sensitivity (98%) in diagnosing pulmonary TB with smear-positive sputum; however, the sensitivities of Xpert in pulmonary TB with smear-negative sputum (67%), in HIV-positive participants (81%), and in children (62%) are considered suboptimal (3). Furthermore, it has also been reported that Xpert occasionally gives false-positive results when used for detecting RIF resistance due to the silent mutations in the \textit{rpoB} gene or samples with very low bacterial loads (4). Consequently, the next-generation cartridge, Xpert MTB/RIF Ultra (Xpert Ultra) (Cepheid Inc., Sunnyvale, CA, USA), was developed and expected to improve the diagnosis of TB and RIF resistance and was recommended by the WHO in March 2017 (5). Consistent outcomes from different studies demonstrated higher sensitivity but lower specificity of Xpert Ultra compared to Xpert, and false-positive results were often obtained from patients who had TB histories (6–9). Because the compromised specificity of the Xpert Ultra assay is largely based on trace results, its interpretation and how to translate it into daily clinical practice remain controversial (10, 11). As country-level tuberculosis incidence rates seem to affect the specificity of Xpert Ultra, further research in high burden settings is needed to clarify the implications of the trade-off between increased sensitivity and decreased specificity.

Previous on-site evaluation studies of Xpert Ultra from China have mainly focused on extrapulmonary tuberculosis specimens or pulmonary TB from a single center with very small sample size (12, 13). Studies including multiple centers and a large-scale pulmonary TB sample size have never been performed in China, which is a high tuberculosis and multidrug-resistant tuberculosis burden setting. Evaluation of the performance and potential application of this advanced diagnostic in the real world is of high importance.

FIG 1 Recruitment and diagnostic classification of the participants

The WHO recommended the Xpert MTB/RIF assay (Xpert) (Cepheid Inc., Sunnyvale, CA, USA) as the initial test for pulmonary TB in 2010 (2). Xpert shows excellent sensitivity (98%) in diagnosing pulmonary TB with smear-positive sputum; however, the sensitivities of Xpert in pulmonary TB with smear-negative sputum (67%), in HIV-positive participants (81%), and in children (62%) are considered suboptimal (3). Furthermore, it has also been reported that Xpert occasionally gives false-positive results when used for detecting RIF resistance due to the silent mutations in the \textit{rpoB} gene or samples with very low bacterial loads (4). Consequently, the next-generation cartridge, Xpert MTB/RIF Ultra (Xpert Ultra) (Cepheid Inc., Sunnyvale, CA, USA), was developed and expected to improve the diagnosis of TB and RIF resistance and was recommended by the WHO in March 2017 (5). Consistent outcomes from different studies demonstrated higher sensitivity but lower specificity of Xpert Ultra compared to Xpert, and false-positive results were often obtained from patients who had TB histories (6–9). Because the compromised specificity of the Xpert Ultra assay is largely based on trace results, its interpretation and how to translate it into daily clinical practice remain controversial (10, 11). As country-level tuberculosis incidence rates seem to affect the specificity of Xpert Ultra, further research in high burden settings is needed to clarify the implications of the trade-off between increased sensitivity and decreased specificity.

RESULTS

Patient characteristics. In total, 1,445 participants were enrolled at the three sites (Fig. 1). Among the 1,105 participants in the case detection group, 26 cases were
excluded and 1,079 patients were included in the analyses, which included 349 definite pulmonary TB (32.34%), 216 probable pulmonary TB (20.02%), and 514 non-TB (47.64%) cases. In contrast, among the 669 participants in the RIF resistance detection group, 219 cases were excluded and the final sample size for analysis was 450 patients, which included 323 RIF-susceptible pulmonary TB (71.80%) and 127 RIF-resistant pulmonary TB (28.22%) cases. All patients were HIV-uninfected. The median age was 57 years, with women making up about one-third (29.44%) of the participants. Basic characteristics stratified by hospital are shown in Table 1.

**Performance of Xpert Ultra in pulmonary TB diagnosis.** Against the mycobacterial culture reference standard, the direct head-to-head comparative accuracy for Mtb detection showed that Xpert Ultra had higher sensitivity than Xpert (92.26%, 322/349 versus 89.40%, 312/349; \( P = 0.006 \)). According to the analysis after stratification by the smear outcomes, Xpert Ultra showed significantly higher sensitivity than Xpert among culture-positive smear-negative sputum (83.70%, 113/135 versus 78.52%, 106/135; \( P = 0.039 \)). Both Xpert Ultra (97.66%, 209/214) and Xpert (96.26%, 206/214) showed excellent performance in diagnosing pulmonary TB from culture-positive smear-positive sputum (Table 2). When Xpert Ultra outcomes were integrated for diagnosis, 83 of the 216 (38.43%) probable pulmonary TB cases were found to have bacteriologic evidence.

The specificity of Xpert Ultra was slightly lower than Xpert (96.30%, 495/514 versus 98.25%, 505/514; \( P = 0.055 \)), although the difference was not statistically significant (Table 2). Among the 19 patients with false-positive Xpert Ultra outcomes, 5 had a known pulmonary TB history, whereas another 2 had NTM infections (one *Mycobacterium intracellulare* infection and one *Mycobacterium kansassi* infection), 1 had lung cancer, and 11 had pneumonia.

**Performance of trace semiquantitation reclassification.** Twenty-eight pulmonary TB cases and 7 non-TB patients produced trace results with Xpert Ultra. To further elucidate the significance of trace, these cases were assigned to different categories. (i) True-positive (57.14%, 20/35): samples with positive outcome by any of smear (2 cases), culture (14 cases) or Xpert (15 cases), or by other tests during follow up (1 case). (ii) Possible true-positive (22.86%, 8/35): samples collected from probable pulmonary TB

| TABLE 1 Characteristics of study participants stratified by hospital |
|---------------------|---------------------|---------------------|---------------------|
| Characteristics     | Overall             | Beijing chest hospital | Shandong provincial chest hospital | Fuzhou pulmonary hospital of Fujian |
| Demographic or clinical characteristics | | | |
| Age, median (range), yr | 57 (7–95) | 56 (15–95) | 51 (7–91) | 57 (15–93) |
| Gender (Male/Female) | 973/406 | 273/105 | 328/184 | 372/117 |
| HIV infection       | 0/1379 | 0/378 | 0/512 | 0/489 |
| History of tuberculosis | 68/1379 (4.93) | 13/378 (3.44) | 11/512 (2.15) | 44/489 (9.00) |
| Enrolment group     | | | | |
| Case detection group | 1079 | 217 | 443 | 419 |
| Rifampicin resistance risk group | 669 | 274 | 217 | 178 |

| TABLE 2 Performance of Xpert and Xpert Ultra for diagnosing pulmonary tuberculosis |
|---------------------|---------------------|---------------------|
|                      | Xpert              | Xpert Ultra         | \( P \) value |
| Sensitivity          |                     |                     |               |
| Definite pulmonary TB| 312/349 (89.40)     | 322/349 (92.26)     | 0.006         |
| Culture positive smear positive | 206/214 (96.26) | 209/214 (97.66) | 0.250         |
| Culture positive smear negative | 106/135 (78.52) | 113/135 (83.70) | 0.039         |
| Probable pulmonary TB | 66/216 (30.56) | 83/216 (38.43) | \(<0.001\) |
| Specificity          |                     |                     |               |
| Positive predictive value | 505/514 (98.25) | 495/514 (96.30) | 0.055         |
| Negative predictive value | 312/321 (97.20) | 322/341 (94.43) | 0.077         |

July/August 2022 Volume 10 Issue 4 10.1128/spectrum.00949-22
patients without other bacteriological evidence, and (iii) False-positive (20.00%, 7/35): 7 patients with excluded or improbable diagnosis of TB, including 3 with history of TB.

An additional analysis was conducted to assess the effect of reclassifying trace results as negative on Xpert Ultra test performance. This resulted in a 4.01% loss of sensitivity (from 92.26% to 88.25%) accompanied by a 1.37% gain in specificity (from 96.30% to 97.67%). However, there was a greater loss in sensitivity in the smear-negative pulmonary TB, where sensitivity dropped by 8.89% (from 83.70% to 74.81%).

Performance of Xpert Ultra in detecting RIF resistance. Four hundred fifty cases produced phenotypic DST outcomes and eligible Xpert and Xpert Ultra RIF resistance results. Against the reference standards of phenotypic DST, both the sensitivity (97.64%, 124/127 versus 88.25% 126/127; \( P = 0.313 \)) and specificity (96.90%, 313/323 versus 97.67%, 314/323; \( P = 0.816 \)) of Xpert Ultra and Xpert for detecting RIF resistance were comparable.

Thirteen participants produced discordant RIF drug susceptibility testing results among Xpert, Xpert Ultra, and phenotypic DST. The \( rpoB \) gene was sequenced to elucidate the RIF susceptibility status. Notably, resistance reported by Xpert or Xpert Ultra was always accompanied with a mutation in the target sequence (Table 3). CTG533CCG (38.46%, 5/13) was the most frequently observed mutation; the second most frequently observed mutation was CTG511CCG (21.43%, 3/14). Furthermore, one specimen reported as phenotypic susceptible but RIF resistant by both Xpert and Xpert Ultra actually had a synonymous mutation at codon 517 (CAG\rightarrow CAA). According to the sequencing data of the specimens with RIF resistance by Xpert Ultra but RIF susceptible by phenotypic DST, specificity of 98.74% (313/317) for Xpert Ultra was obtained.

**DISCUSSION**

Xpert Ultra has been reengineered to improve diagnostic performance with a lower analytic limit of detection. Although slightly increased sensitivity in detection was acquired with sputum, a decrease in specificity raises concerns about its practical value (6, 7). As the compromised specificity of Xpert Ultra is closely related with the TB history of the subject, different TB prevalence rates would affect Xpert Ultra’s performance in different countries. Hence, the performance of Xpert Ultra was compared head to head with its first-generation counterpart, i.e., Xpert assay, in this multicentered study in China.

Among the 349 definite pulmonary TB patients, Xpert Ultra was only 2.86% (92.26% versus 89.40%) more sensitive than Xpert overall and 5.18% (78.52% versus 83.70%) more sensitive among smear-negative pulmonary TB cases. Our results were in line with previous reports, which showed that using culture as the gold standard the

| Participant ID | Site     | Rifampin phenotypic DST result | Xpert rifampin result | Xpert Ultra rifampin result | \( rpoB \) gene mutation |
|---------------|----------|--------------------------------|-----------------------|-----------------------------|--------------------------|
| 151504        | Beijing  | S                              | R                     | R                           | CAG517CAA                |
| 147767        | Beijing  | S                              | R                     | R                           | CTG533CCG                |
| 151202        | Beijing  | S                              | R                     | R                           | CTG511CCG                |
| 252826        | Shandong | S                              | R                     | R                           | CTG511CCG                |
| 512850        | Shandong | S                              | R                     | R                           | CTG533CCG                |
| 513668        | Shandong | S                              | R                     | R                           | CTG533CCG                |
| 261668        | Shandong | S                              | R                     | R                           | CTG533CCG                |
| 192104        | Shandong | S                              | S                     | R                           | CAC526AAC                |
| 512834        | Shandong | S                              | R                     | R                           | CTG533CCG                |
| 512949        | Shandong | S                              | R                     | R                           | CTG511CCG                |
| 133245        | Beijing  | R                              | R                     | S                           | GAC516GGC                |
| 512834        | Shandong | S                              | R                     | S                           | TCG531TTG                |
| 192104        | Shandong | R                              | R                     | S                           | CTG511CCG                |
| 192104        | Shandong | R                              | R                     | S                           | Wild type                |

*a* S, susceptible; R, resistant.
pooled sensitivity of Xpert Ultra in diagnosing pulmonary TB was 84%–91% versus 69%–85% pooled sensitivity for Xpert (9, 14, 15). These results indicate that Xpert Ultra is highly beneficial for diagnosing paucibacillary pulmonary TB patients. Several studies also reported that Xpert Ultra significantly improved the diagnosis of extrapulmonary TB and childhood TB with paucibacillary features (12, 16–18), while comparable specificity was acquired in contrast to the Xpert assay.

Xpert Ultra has an additional category called “trace” in contrast to Xpert. The “trace” category is mainly responsible for the improvement in the limit of detection and reduced specificity of Xpert Ultra. However, it is critical to appropriately interpret the trace readout in clinical practice in order to take advantage of the increased sensitivity and avoid false-positive outcomes. Reclassification of trace results as negative in this study resulted in a 1.37% gain in specificity (from 96.30% to 97.67%); however, the sensitivity in smear-negative pulmonary TB also dropped by 8.89% (from 83.70% to 74.81%). Berhanu et al. (19) reported that reclassification of trace results caused 5.6% loss of sensitivity in the smear-negative group. Dorman et al. (6) showed that the reduction in sensitivity from excluding the trace readout was almost 9% in smear-negative culture-positive persons. Thus, if trace results were reclassified to elevate specificity, Xpert Ultra would lose its sensitivity-associated benefit over Xpert. We have summarized the trace-positive rate of several previous reports (Table 4), which show that trace-positive results are relatively infrequent (<6%) in non-TB patients, except for those with a history of TB treatment within 2 years (15.32%). Furthermore, more than half of the trace outcomes were confirmed by other tests (57.14%, 20/35) in this study. In a highly notable event, one “non-TB” patient, who yielded trace outcome for Xpert Ultra and very low positive outcome for Xpert assay, produced positive molecular outcome during follow-up and was subsequently reclassified as a TB patient. Overall, the influence of TB burden on specificity of Xpert Ultra in China was lower than what we had predicted. Our findings support the potential role of Xpert Ultra as the initial diagnostic tool for pulmonary TB.

Although the decreased specificity of Xpert Ultra is a noteworthy concern for its application in diagnostics in high TB burden settings, we did not observe significantly lower specificity for it compared with Xpert assay (96.30% versus 98.25%, \(P = 0.055\)). In addition, despite the fact that 15.95% (82/514) of the non-TB participants had a known TB history, only three of them yielded trace outcomes. A majority of the participants had a history of TB extending beyond 2 years; hence, it is plausible that this is the main reason that TB history did not significantly affect the specificity of Xpert Ultra in this study. Therefore, our study supports the practical value of performing Xpert Ultra in China.

Multidrug-resistant TB continues to remain as a concern globally. Xpert Ultra was developed to improve the specificity in detection of RIF resistance; however, we did not observe this improvement over Xpert assay in this study. Here, Xpert Ultra and Xpert displayed comparable sensitivity (97.64% versus 99.21%) and specificity (96.90% V.S. 97.21%) for the detection of RIF resistance, consistent with other reports (20, 21). This could be explained by the fact that the increased sensitivity of Xpert Ultra mainly gives credit to the trace semi-qualification outcome target IS6110/IS1083, which has no relation with RIF resistance.

Based on ours and other studies, we suggest two different strategies for the application of Xpert Ultra, considering the cost of Xpert Ultra on the market. When the price of Xpert Ultra assay is similar to that of Xpert assay, Xpert Ultra could be used as a surrogate to the Xpert essay as the initial TB diagnostic test. On the other hand, if the cost of Xpert Ultra assay is obviously higher than Xpert assay, we suggest that Xpert Ultra be used as the initial diagnostic test for paucibacillary TB, such as extrapulmonary TB and childhood TB, while for a pulmonary TB suspect with a negative initial Xpert assay, an additional Xpert Ultra test could be performed to improve case finding.

A strength of our study is that it is a prospective multicenter study with a large number of consecutively enrolled participants in a clinical routine setting. The study population is thus more likely to be representative of the true test population in a high TB prevalence country. But the study’s limitations should also be noted. First, the realistic TB history prevalence rate in the non-TB group is not known. Some participants might have self-recovered undiagnosed TB or have a previously unknown history of TB, which happens frequently in
### TABLE 4 Xpert Ultra trace-positive rate of several studies

| Author          | Year | Country                                                                 | Sample size | Sample type       | Culture-positive (%) | Trace-positive rate (%) |
|-----------------|------|-------------------------------------------------------------------------|-------------|-------------------|-----------------------|-------------------------|
| Dorman SE, et al. (6) | 2018 | South Africa, Uganda, Kenya, India, China, Georgia, Belarus, Brazil    | 1,439       | Sputum            | 32.11 (462/1439)     | 2.22 (32/1439) 2.81 (13/462) 1.94 (19/977) |
| Berhanu RH, et al. (19) | 2018 | Johannesburg, South Africa                                              | 237         | Sputum            | 23.63 (56/237)       | 2.53 (6/237) 1.79 (1/56) 2.76 (5/181) |
| Opota O, et al. (21)   | 2019 | Switzerland                                                             | 196         | Respiratory sample | 23.98 (47/196)      | 5/196 8.51 (4/47) 0 (0/149) |
| Mishra H, et al. (7)   | 2020 | South Africa                                                            | 239         | Sputum            | 30.13 (72/239)      | 5.44 (13/239) 5.56 (4/72) 5.39 (9/167) |
| Mishra H, et al. (7)   | 2020 | South Africa                                                            | 168         | Sputum*           | 26.19 (44/168)      | 12.50 (21/168) 4.55 (2/44) 15.32 (19/124) |
| Esmail A, et al. (11)  | 2020 | South Africa                                                            | 268         | Sputum            | 62.69 (168/268)     | 3.36 (9/268) 3.57 (6/168) 3.00 (3/100) |
| Andama A, et al. (24)  | 2021 | Uganda                                                                  | 698         | Sputum            | 3.01 (21/698)       | 4.76 (16/336) 0.00 (0/0) 1.38 (5/362) |
| Zhang P, et al. (13)   | 2021 | China                                                                   | 99          | Bronchoalveolar lavage | 25.25 (25/99)      | 5.95 (5/99) |
| Our study            | 2021 | China                                                                   | 1,079       | Sputum            | 32.34 (349/1079)    | 3.23 (35/1079) 4.79 (27/564) 1.55 (8/155) |

*Patients with presumptive tuberculosis and recent previous tuberculosis (≤ 2 years).
high TB burden settings. However, these possibilities, together with that of the people with known TB history, were evaluated as a whole in this study. Second, only smear-positive sputas were recruited in the RIF resistance detection group. Smear-negative samples are a major source of false RIF resistant results of the Xpert assay. No improvement in specificity of RIF resistance detection of Xpert Ultra was observed in this study, which might relate to the exclusion of smear-negative samples.

In conclusion, Xpert Ultra is more sensitive than Xpert, especially in smear-negative pulmonary TB. A high percentage of TB history in the non-TB population did not significantly affect the reliability of the test, which supports the potential role of Xpert Ultra as an initial diagnostic tool for TB. If the cost of Xpert Ultra assay is similar to Xpert assay, Xpert Ultra could be used as the initial diagnostic; otherwise, an additional Xpert Ultra assay could be performed after Xpert assay producing a negative outcome to improve case finding.

MATERIALS AND METHODS

Ethical approval. The study was approved by the ethics committees of the three hospitals separately. Because all the samples used were leftover specimens from routine clinical examinations, written informed consent of the patient was waived.

Study design and participants. Participants were enrolled consecutively from July 2019 to November 2020 in three tertiary hospitals from three different provinces: Beijing Chest Hospital (Beijing, China), Shandong Provincial Chest Hospital (Jinan, Shandong province, China), and Fuzhou Pulmonary Hospital of Fujian (Fuzhou, Fujian province, China). The TB incidence rate was about 35/100,000, 26/100,000 and 33/100,000 in 2020 in Beijing municipality, Shandong province and Fuzhou province, respectively (according to the Chinese infectious diseases reporting system). Based on the purpose of the test, two different recruitment criteria were applied. The TB case detection group, recruited patients with presumptive pulmonary TB, defined as a case presenting symptoms or signs suggestive of pulmonary TB as per the standard criteria of WHO (22); administered anti-TB drug for ≤3 days in the past 6 months; with more than 5 mL sputum. For the RIF resistance detection group, patients with smear positive sputum and enough volume were recruited consecutively, regardless of their anti-TB treatment status. Patients in the RIF resistance detection group overlapped partially with the case detection study but also included retreated patients or relapse TB cases. Each sputum specimen was processed with smear, culture, Xpert and Xpert Ultra assay, simultaneously. Drug susceptibility testing (DST) and rpoB gene sequencing was conducted for all of the isolates recovered in the RIF resistance detection group.

Patient categories. Definite pulmonary TB, defined as microbiologically confirmed TB, with positive smear and/or culture outcome excluding nontuberculous mycobacteria (NTM). Probable TB, defined as neither smear nor culture, was positive, the patient was clinically diagnosed as TB based on clinical findings, radiologic imaging, other molecular tests, or the response to empirical anti-TB treatment. Non-TB indicated that the cases were diagnosed as other diseases, or that the laboratory testing was not suggestive of TB, and the patient improved without receiving antituberculosis treatment. The drug susceptibility status of the patient was referred to the phenotypic DST outcomes.

Smear and culture. Direct smear was prepared and stained with auramine and examined by light-emitting diode microscopy. After processing with NALC/NaOH and centrifugation, the resuspended sputum pellet was subjected to culture in a liquid medium using the MGIT 960 system (BD Diagnostic Systems, NJ, USA). For all the isolates, MPIT64 antigen testing was performed to confirm the presence of M. tuberculosis (Mtb) complex.

Xpert and Xpert Ultra. The Xpert and Xpert Ultra assays were performed as per the manufacturer’s instructions. Briefly, 1 mL sputum specimen was mixed with 2 mL sample reagent, vortexed for at least 10 s, and incubated at room temperature for 15 min. A total of 2 mL from the mixture was transferred into the cartridge and loaded into the GeneXpert instrument (Cepheid Inc., Sunnyvale, CA, USA). The automatic detection procedure was then run. For an invalid result, a repeat Xpert and/or Xpert Ultra test was performed on the same sample. Semiquantitative estimation of the Mtb load was also determined by Xpert Ultra as high, medium, low, very low, or trace, depending on the cycle threshold.

Drug susceptibility testing. Culture positive samples were subjected for phenotypic DST using the Bactec MGIT 960 system (BD Diagnostic Systems, NJ, USA). The critical concentration of 1 mg/mL was used for RIF.

rpoB gene sequencing. Isolates were further analyzed by sequencing of an internal region of the rpoB gene, which included the RIF resistance-determining region (RRDR), in order to identify mutations associated with RIF resistance. The rpoB gene was amplified using a previously published method (23). DNA sequences were analyzed and compared with the sequence of the Mtb reference strain H37Rv using Lasergene software version 7.1.

Statistical analyses. The sensitivity, specificity, positive predictive value, and negative predictive value of different assays were calculated against the reference standard. The McNemar’s test was used to compare the sensitivity and specificity of Mtb or RIF detection between Xpert and Xpert Ultra. Statistical analysis was performed using SPSS version 19.0. Differences were considered statistically significant at P < 0.05.

ACKNOWLEDGMENTS

This work was supported by the Beijing Public Health Experts Project (2022-3-040), Tongzhou Yunhe Project under Grant (YH201917), Beijing Tongzhou Municipal Science
& Technology commission (KJ2022CX044), and Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20181602).

H.H., G.J., and Y.D. made substantial contributions to the conception or design of the work; G.W., M.H., H.J., L.D., L.Z., F.W., and Y.X. acquired, analyzed, and interpreted the data; G.W. and H.H. wrote the first draft; G.W., M.H., H.J., L.D., L.Z., F.W., Y.X., H.H., G.J., and Y.D. revised the work for important intellectual content and approved the version to be published.

We have no conflicts of interest to report.

REFERENCES
1. World Health Organization. 2021. Global tuberculosis report 2021. Geneva, Switzerland: World Health Organization.
2. World Health Organization. 2011. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland: World Health Organization.
3. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dedukuri N. 2014. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev CD009593. https://doi.org/10.1002/14651858.CD009593.pub3.
4. Hu P, Zhang H, Fleming J, Zhou G, Zhang S, Wang Y, Liu F, Yi S, Chen Z, Chen Z, Liu B, Gong D, Lan W, Wang X, Tan Y, Bai L, Bi L. 2019. Retrospective analysis of false-positive and disputed rifampin resistance Xpert MTB/RIF assay results in clinical samples from a referral hospital in Hunan, China. J Clin Microbiol 57:e00170-18. https://doi.org/10.1128/JCM.00170-18.
5. World Health Organization. 2017. WHO meeting report for a technical expert consultation: no-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva, Switzerland: World Health Organization.
6. Dorman SE, Schumacher SG, Alland D, Nabetta P, Armstrong DT, King B, Hall SL, Chakravorty S, Critillo DM, Tukvadze N, Sabilishvili N, Stevens W, Scott L, Rodrigues C, Kazi M, Joloba M, Nakiyangi L, Nicol MP, Ghebrekristos Y, Anyango I, Murtithi W, Dietze R, Lyrio Peres R, Skrahina A, Aychunyka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM, study team. 2018. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76–84. https://doi.org/10.1016/S1473-3099(17)30691-6.
7. Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG, Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM, Theran G. 2020. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med 8:369–382. https://doi.org/10.1016/S2213-2600(19)30370-4.
8. Opota O, Zakkham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. 2019. Added value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. J Clin Microbiol 57:e01717-18. https://doi.org/10.1128/JCM.01717-18.
9. Zifodey JS, Kreniske JS, Schiller I, Kohli M, Dedukuri N, Schumacher SG, Ochoho EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. 2021. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev 2:CD009593. https://doi.org/10.1002/14651858.CD009593.pub5.
10. Mazolla E, Monte PD, Pierismoni C, Guudice AD, Camaggi A, Pedrotti C, Gurrieri F, Russo C, Farina C, Lambardi A, Viggiani P, Cenci E, Nistico S, Rognoni V, Sala E, Cicero P, Frizerra E, Monzillo V, Morini F, Scarapoto C, Borroni E, Critillo DM, Tortoli E. 2021. Multicenter evaluation of Xpert MTB/RIF Ultra tests reporting detection of “trace” of Mycobacterium tuberculosis DNA. Int J Mycobacteriol 10:101–103.
11. Esmail A, Tomasichchio M, Meldau R, Makambwa M, Dheda K. 2020. Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. Int J Infect Dis 95:246–252. https://doi.org/10.1016/j.ijid.2020.03.025.
12. Wang G, Wang S, Jiang G, Yang X, Huang M, Hoo F, Ma Y, Dai G, Li W, Chen X, Huang H. 2019. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. J Infect 78:311–316. https://doi.org/10.1016/j.jinf.2019.02.010.
13. Zhang P, Liu H, Wang H, Wu Y, Sun L, Rao M, Jia X, Song Y, Deng G, Li T, Ye F, Zhou Y, Liao Y. 2021. Performance of Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis using bronchoalveolar lavage samples in people living with HIV/AIDS (PLWHA) in China: a prospective study. HIV Volume 13:905–916. https://doi.org/10.2147/HIV.S319117.
14. Jiang J, Yang J, Shi Y, Jin Y, Tang S, Zhang N, Lu Y, Sun G. 2020. Head-to-head comparison of the diagnostic accuracy of Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis: a meta-analysis. Infect Dis (Lond) 52:763–775. https://doi.org/10.1080/23744235.2020.1788222.
15. Zhang M, Xue M, He JQ. 2020. Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. Int J Infect Dis 90:35–45. https://doi.org/10.1016/j.ijid.2019.09.016.
16. Wang G, Wang S, Yang X, Sun Q, Jiang G, Huang M, Hoo F, Ma Y, Chen X, Huang H. 2020. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest 157:268–275. https://doi.org/10.1016/j.chest.2019.07.027.
17. Sun Q, Wang S, Dong W, Jiang G, Hoo F, Ma Y, Huang H, Wang G. 2019. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. J Infect 79:153–158. https://doi.org/10.1016/j.jinf.2019.06.006.
18. Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasmamol M, Kamwela L, Haraka F, Hoelscher M, Paris DH, Saathoff E, Reither K. 2018. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. J Infect 77:321–327. https://doi.org/10.1016/j.jinf.2018.07.002.
19. Berhanu RH, David A, da Silva P, Shearer K, Sanne I, Stevens W, Scott L. 2018. Performance of Xpert MTB/RIF, Ultra, and Abbott RealTime MTB for diagnosis of pulmonary tuberculosis in a high-HIV burden setting. J Clin Microbiol 56:e00560-18. https://doi.org/10.1128/JCM.00560-18.
20. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Critillo DM, Dawidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. 2017. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8:e00812-17. https://doi.org/10.1128/mBio.00812-17.
21. Opota O, Mazza-Stalder J, Greub G, Jaton K. 2019. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clin Microbiol Infect 25:1370–1376. https://doi.org/10.1016/j.cmi.2019.03.021.
22. World Health Organization. 2019. Tuberculosis (TB). Systematic screening for active tuberculosis: principles and recommendations. Geneva, Switzerland: World Health Organization.
23. Huo F, Ma Y, Liu R, Ma L, Li S, Jiang G, Wang F, Shang Y, Dong L, Pang Y. 2020. Interpretation of discordant rifampicin susceptibility test results obtained using GeneXpert vs Phenotypic Drug Susceptibility Testing. Open Forum Infect Dis 7:ofaa279. https://doi.org/10.1093/ofid/ofaa279.
24. Andama A, Jaganath D, Crowder R, Asege L, Nakaye M, Katumba D, Mukwatamundu J, Mwebe S, Semitala CF, Worodria W, Joloba M, Mohanty S, Somoski C, Attamani A. 2021. The transition to Xpert MTB/RIF Ultra: diagnostic accuracy for pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis 21(1):49. https://doi.org/10.1186/s12879-020-05277-8.